# US 8,771,678 B2 · Methods of using adipose tissue-derived cells in augmenting autologous fat transfer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,771,678 B2 - Document ID: US8771678B2 - Status: Granted - Kind: B2 - Application number: 13/588,989 - Filed: 2012-08-17 - Published: 2012-12-06 - Granted: 2014-07-08 - Earliest claimed: 2001-12-07 - Assignees: Cytori Therapeutics, Inc. - Applicants: Marc H. Hedrick; John K. Fraser - Inventors: Marc H. Hedrick; John K. Fraser - Web page: https://patentgrep.com/patent/US8771678B2 ## CPC - A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells - A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells - A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel} - A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells} - A61L 27/3886: {comprising two or more cell types} - A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} - A61M 1/893: {with extraction of specific components, e.g. of stem cells} - A61M 1/895: {with means for reinjection of collected fat} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 3/06: Antihyperlipidemics - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 17/00: Drugs for dermatological disorders - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells} - C12N 5/069: {Vascular Endothelial cells} - A61L 2300/414: Growth factors - A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus - A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons - A61L 2430/34: for soft tissue reconstruction - C12N 2506/1384: from adipose-derived stem cells [ADSC], from adipose stromal stem cells - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed. ## Claims ### Claim 1 A method of augmenting autologous fat transfer to a subject, comprising: removing a first portion of adipose tissue that comprises a cell population comprising adipose-derived stem cells and progenitor from said subject; introducing the removed adipose tissue into a self-contained cell processing unit configured to maintain a closed pathway; isolating said cell population that comprises adipose-derived stem cells and progenitor cells from mature adipocytes and connective tissue present in the removed adipose tissue so as to obtain a substantially isolated cell population comprising disaggregated adipose-derived stem cells and progenitor cells, while maintaining a closed pathway; concentrating said substantially isolated cell population comprising disaggregated adipose-derived stem cells so as to obtain a concentrated cell population that comprises disaggregated adipose-derived stem cells and progenitor cells, while maintaining a closed pathway; mixing said concentrated cell population comprising adipose-derived stem cells and progenitor cells with a second portion of unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments obtained from said subject, so as to obtain an adipose tissue composition comprising a mixture of said concentrated cell population comprising disaggregated adipose-derived stem cells and progenitor cells and said unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments tissue; and reintroducing said adipose tissue composition into said subject. ### Claim 2 (depends on 1) The method of claim 1, further comprising providing said mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells to a breast of the subject. ### Claim 3 (depends on 1) The method of claim 1, wherein said subject has radiation trauma. ### Claim 4 (depends on 1) The method of claim 1, further comprising providing said mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells to a soft-tissue region of the subject. ### Claim 5 (depends on 4) The method of claim 4, wherein said soft tissue defect was from irradiation or war injury. ### Claim 6 (depends on 1) The method of claim 1, further comprising providing said mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells to a urethral region of the subject. ### Claim 7 (depends on 1) The method of claim 1, wherein multiple doses of the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells are provided to said subject. ### Claim 8 (depends on 1) The method of claim 1, further comprising providing one or more angiogenic factors to the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells. ### Claim 9 (depends on 1) The method of claim 1, further comprising providing the one or more arteriogenic factors to the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells. ### Claim 10 (depends on 1) The method of claim 1, further comprising providing one or more immunosuppressive drugs to the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells. ### Claim 11 (depends on 1) The method of claim 1, further comprising culturing said concentrated cell population that comprises adipose-derived stem cells and progenitor cells prior to mixing said cell population that comprises adipose-derived stem cells with said second portion of unprocessed adipose tissue comprising intact, non disaggregated tissue fragments from said subject. ### Claim 12 (depends on 11) The method of claim 11 wherein said culturing step comprises exposing said concentrated cell population that comprises adipose-derived stem cells and progenitor cells to culture conditions that promote differentiation towards an endothelial phenotype. ### Claim 13 (depends on 11) The method of claim 11, wherein said culturing step is performed on a scaffold. ### Claim 14 (depends on 13) The method of claim 13, wherein said scaffold is resorbable in vivo.